Next-generation precision oncology

The new standard for cancer care

We’re enabling smarter cancer treatment to ensure every patient gets their best possible therapy

Introducing

Strata Select™

Personalize immunotherapy with one simple score for all solid tumors

  • First-of-its-kind molecular profiling test
  • Provides treatment selection guidance for immunotherapy and beyond
  • Covered by Medicare


IMG_0360_EDIT
Dr. Adam Forman

From Our Partners

“Strata Select meets all of my needs for molecular profiling. The fast turnaround time, comprehensive clinically-relevant genomic information presented in an easy-to-read format, expert pathologist assessment of molecular diagnosis, and small sample size requirements ensure I have everything I need – when I need it – to make the best possible treatment decisions for my advanced cancer patients.”

Dr. Adam Forman, MD

Newland Medical Associates

Dr. Sachdev Thomas

From Our Partners

“Through our research collaboration with Strata Oncology we were able to independently validate the Immunotherapy Response Score (IRS), which fills a critical unmet medical need. Besides TMB and MSI, IRS can independently identify patients who may respond to pembrolizumab across a variety of cancer types (pan-tumor). For IRS High patients — who represent about 20% of all advanced cancer patients — we now have a 1st line single-agent immunotherapy treatment option that can potentially spare patients across many solid tumor types from unnecessary chemotherapy.”

Dr. Sachdev Thomas, MD

Genomic Oncology Lead, Kaiser Permanente Northern California

Our approach

Guiding the next wave of precision oncology innovation

Gene expression-based oncology therapeutics are emerging as important new options for patients. We’re bringing this class of therapies into the precision era with proprietary treatment selection algorithms

Bringing new options to patients with cancer

We’re advancing new precision treatment hypotheses to improve outcomes and utilization

Customers we serve

Working across the healthcare ecosystem to maximize patient benefit

For Providers

Get the insights you need to provide optimal precision cancer care. With industry-low tissue requirements, Strata Select provides treatment selection guidance for immunotherapy and beyond.

For Health Systems

Remain at the forefront of cancer care. Drive better outcomes with a comprehensive, scalable precision oncology program that helps ensure patients receive their optimal therapy.

For Biopharma Partners

Accelerate drug development. Partner with us to leverage our innovative molecular profiling platform and clinical research infrastructure to advance your precision oncology programs.

For Providers

Get the insights you need to provide optimal precision cancer care. With industry-low tissue requirements, Strata Select provides treatment selection guidance for immunotherapy and beyond.

For Health Systems

Remain at the forefront of cancer care. Drive better outcomes with a comprehensive, scalable precision oncology program that helps ensure patients receive their optimal therapy.

For Biopharma Partners

Accelerate drug development. Partner with us to leverage our innovative molecular profiling platform and clinical research infrastructure to advance your precision oncology programs.

Homepage-2

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

September 26, 2023

Strata Oncology Announces Appointment of Goz Alhir as Senior Vice President of Commercialization

September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%